{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T00:01:44Z","timestamp":1697760104636},"reference-count":0,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":["eje.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1983,8]]},"abstract":"<jats:p>Abstract. Eighteen hyperprolactinaemic patients were orally treated for up to 16 months with pergolide mesylate, a new potent long-lasting dopaminergic ergot derivative. In all cases, Prl normalization (&lt; 25 ng\/ml) was achieved at a once-a-day dose of 50\u2013300 \u03bcg. All women recovered and\/or exhibited normal menstrual function. Among the 6 women wishing to become pregnant, 4 of them conceived within 4 months; there were other causes for infertility than hyperprolactinaemia in the 2 other couples.<\/jats:p>\n          <jats:p>A macroprolactinoma man experienced important improvement in well-being as well as objective regression of his visual fields defect. This suggests a shrinkage effect of pergolide on the tumoural process. Another man regained normal potency and normal testosterone within 2 weeks.<\/jats:p>\n          <jats:p>While 10 patients were completely free of any side effect, 7 experienced transiently mild gastro-intestinal side effects or postural hypotension. Only one patient discontinued her treatment because of dizziness.<\/jats:p>\n          <jats:p>The present study demonstrates the high potency, the good tolerance and the excellent efficacy of pergolide in the treatment og hyperprolactinaemia.<\/jats:p>","DOI":"10.1530\/acta.0.1030441","type":"journal-article","created":{"date-parts":[[2008,12,15]],"date-time":"2008-12-15T21:53:47Z","timestamp":1229378027000},"page":"441-445","update-policy":"http:\/\/dx.doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":4,"title":["Treatment of hyperprolactinaemic patients with pergolide"],"prefix":"10.1093","volume":"103","author":[{"given":"Marc","family":"L'Hermite","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre M.","family":"Debusschere","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mentine","family":"Gillet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Deschepper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","container-title":["Acta Endocrinologica"],"original-title":[],"link":[{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/103\/4\/acta_103_4_002.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eje.bioscientifica.com\/view\/journals\/eje\/103\/4\/acta_103_4_002.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T16:16:07Z","timestamp":1676391367000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/103\/4\/441\/6795639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,8]]},"references-count":0,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1530\/acta.0.1030441","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,8]]}}}